Alimera Sciences (NASDAQ:ALIM) Earns “Neutral” Rating from Alliance Global Partners

Alliance Global Partners reissued their neutral rating on shares of Alimera Sciences (NASDAQ:ALIM) in a research note published on Tuesday, Marketbeat.com reports.

A number of other research analysts also recently commented on the stock. HC Wainwright downgraded shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective on the stock. in a research note on Tuesday. Maxim Group reissued a hold rating on shares of Alimera Sciences in a report on Tuesday. Finally, StockNews.com cut shares of Alimera Sciences from a buy rating to a hold rating in a research note on Tuesday, April 30th.

Alimera Sciences Stock Performance

NASDAQ:ALIM opened at $5.56 on Tuesday. The stock has a market cap of $291.29 million, a PE ratio of -3.54 and a beta of 1.14. Alimera Sciences has a fifty-two week low of $2.60 and a fifty-two week high of $5.65. The firm’s fifty day simple moving average is $3.48 and its 200-day simple moving average is $3.69. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The firm had revenue of $23.01 million during the quarter, compared to analysts’ expectations of $23.72 million. During the same period in the previous year, the firm posted ($0.71) earnings per share. Analysts expect that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC increased its position in shares of Alimera Sciences by 0.4% during the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock worth $17,278,000 after purchasing an additional 15,773 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the period. Worth Venture Partners LLC bought a new stake in Alimera Sciences in the third quarter valued at about $1,840,000. Ancora Advisors LLC bought a new stake in Alimera Sciences in the first quarter valued at about $915,000. Finally, Hillsdale Investment Management Inc. acquired a new position in Alimera Sciences in the first quarter valued at about $169,000. 99.83% of the stock is owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).